Diabetes mellitus results from inadequate insulin action, which can be viewed as a consequence of the limited ability to restore b cells after they are lost as the result of metabolic exhaustion, autoimmune destruction, or surgical insult. Arguably, a uniformly effective therapeutic pathway to address all forms of diabetes would be to reverse the restrictions on b-cell and islet regeneration. The development from progenitor cells of islets with normal endocrine function does occur in adult humans; it is referred to as islet neogenesis. The induction of islet neogenesis is an important, if not essential, therapeutic approach for curing type 1 diabetes mellitus (T1DM) and could be valuable in the treatment of type 2 diabetes mellitus (T2DM) as well. Islet neogenesis associated protein (INGAP) is the first therapeutic candidate to be identified as the result of a purposeful search for an endogenous molecule with islet neogenic activity. It was found that partial obstruction of the pancreatic duct in hamsters induced islet neogenesis; under this condition, a neogenesis-promoting activity was identified and partially purified from a soluble tissue fraction. A 168-kDa protein product of the cloned gene was found to be responsible for the neogenesis activity. This molecule named INGAP contains an active core sequence of amino acids called INGAP peptide. Results from in vitro, animal, and human studies suggest that INGAP and INGAP peptide are neogenic in at least several vertebrate species, including humans. INGAP has since been found to be a member of the family of Reg proteins, which are found across and in multiple versions within species and are closely associated with embryonic and regenerative processes. Clinical results suggest that INGAP peptide can be a suitable neogenesis therapy, but optimization of the therapy and more data are required to fully access this potential. Understanding of the signaling pathways of INGAP and other related Reg proteins is a promising means of advancing therapeutic development for people with T1DM and T2DM. The quest for the fundamental restorative approach to lost insulin secretion is an enticing target for drug development.
Introduction
Di abetes mellitus results from inadequate insulin action, which can be viewed as a consequence of the limited ability to restore b cells after they are lost as a result of metabolic exhaustion, autoimmune destruction, or surgical insult. Arguably, a uniformly effective therapeutic pathway to address all forms of diabetes would be to reverse the restrictions on b-cell and islet regeneration imposed during the developmental process. Definitive therapeutic approaches will also include control of the autoimmune processes of type 1 diabetes (T1DM) 1 and the metabolic defects underlying type 2 diabetes (T2DM), 2 but the sine qua non for curing any form of established diabetes is to restore lost b cells. A cure of established diabetes-particularly T1DM-will therefore almost certainly involve a form of islet regeneration. The induction of islet regeneration from existing progenitor cells is termed neogenesis, the subject of this review. This review focuses on a particular candidate therapy for islet neogenesis, in part, because human trials of islet neogenesis associated protein (INGAP) peptide conducted in both T1DM and T2DM patients provide clinical experience and teach a number of principles and lessons for the development of any neogenesis therapy. This review can only present high-level summaries of the relevant advances that have been made in developmental biology, immunology, and transplantation technology. Each of these important facets of neogenesis has been discussed in depth in recently published excellent reviews. [3] [4] [5] [6] [7] Addressing Unmet Clinical Need After Banting and Best's animal experiments, which culminated in the discovery of insulin therapy, there were probably many who believed that diabetes had largely been conquered. Despite the significant advances in insulin manufacture, modification, and delivery since that time, the treatment of the absolute insulin deficiency resulting from T1DM is very challenging. Insulin administration remains relatively hazardous and not fully effective in preventing complications, even if managed meticulously. 8 In the meantime, T2DM has become a global health crisis. 9 Diabetes in general and insulin use in particular have become impediments to maintaining employment and licenses to operate equipment, including motor vehicles. 10 Fortunately, new therapies have been developed, which not only improve the metabolic disorder of T2DM but appear to reduce the loss of b-cell function. 11 These therapies may help reduce the proportion of people with T2DM 12 who require insulin therapy, but it is doubtful that this need will be eliminated.
In contrast to these approved therapies and others soon to follow, which appear to improve b-cell health and perhaps even stimulate b-cell replication, a true neogenesis agent gives the prospect of restoring lost islet function (not simply maintaining b-cell mass and function). An effective neogenesis therapy will give people with either T1DM or T2DM the chance to reduce or eliminate their need for insulin therapy. Although animal data have suggested that GLP-1 agonists such as exenatide (Byetta TM, Amilyn) have neogenesis activity, direct evidence of such activity in humans has yet to be reported. Some evidence from nonhuman primates implies that these agonists may not have neogenesis activity in humans. 13 A safe and fully effective neogenesis agent paired with an appropriate immunomodulatory approach would provide definitive therapy for T1DM, resulting in a lifelong remission or an effective "cure" for a population that approaches 1 million people in North America and is growing. 14 Such a therapy could also restore b-cell function in an even larger number of insulin-requiring people with T2DM, thereby returning their endogenous insulin production to levels found in earlier stages of their disease. Even a modest return of islet function and autoregulated insulin secretion would provide a therapeutic advance and substantial clinical benefits for people with either T1DM or T2DM. From a regulatory perspective, the greater unmet need is found among people with T1DM, and neogenesis therapy would provide these patients with an important therapeutic breakthrough in treating their disease. It is emphasized that people with either T1DM or insulin-requiring T2DM would qualitatively benefit clinically from neogenesis in the same ways. However, returning endogenous insulin secretion in T1DM provides the ultimate test and highest hurdle for islet cell regeneration. This review focuses on the application of a neogenesis therapeutic approach to T1DM.
Emerging Technologies to Address This Need
Intermediate technologies for restoring glucose-sensitive insulin secretion include islet transplantation from humans and other animals 15, 16 and "closed-loop" insulin pumps and adult and embryonic stem cell technologies (Figure 1) . Allotransplantation of human islets has shown some clinical value and has provided important understanding of islet biology and immunology. 17, 18 Although promising, it is unlikely that transplantation and mechanical devices can achieve a high level of safety, flawless and enduring performance, and convenience, which would fully satisfy patients and clinicians. [19] [20] [21] [22] [23] [24] Manufacturing of human islets ex vivo for transplantation is a technologically hybrid approach. A number of approaches for producing islets have been reported, including involving INGAP. 4, [25] [26] [27] [28] These technologies could address the current scarcity of human islets for transplantation, but without encapsulation, would not avoid the need for immune therapy required by alloislet transplantation. Broadly speaking, islet transplantation and all versions of the artificial pancreas can be viewed as intact systems that sense ambient glucose concentrations and appropriately release insulin. Any closed loop system, whether tissue transplantation or mechanical device, will require careful installation and maintenance.
Figure 1:
General categories for restoring glucose-dependent insulin secretion. Three major categories are depicted. The biomechanical approach weds two major technologies, glucose sensing and insulin pumping, to achieve a system that maintains normal glucose levels. This system cannot achieve completely normal physiology because only insulin and no other islet hormones are delivered. The site of insulin delivery by this approach is also nonphysiologic. The ex vivo category involves transplantation of islets that may be donated or produced from progenitor cells. Approaches in this category require either systemic immunotherapy of the recipient or encapsulation to prevent immune destruction. Transplanted islets reside outside the pancreas. Reintroduced stem cells may possibly home to the pancreas and develop into islets. The third general category simply involves therapeutically inducing endogenous stem or progenitor cellseither within the pancreas or elsewhere-to developing into islets.
The normal developmental pathway is indicated by .
The other broad category for restoring glucose-sensitive insulin secretion entails inducing progenitor cells to develop into islets that appropriately secrete insulin as well as other endogenous hormones present in normal islet cells. Glucagon, for example, is an important glucose counterregulatory hormone also secreted by islets. [29] [30] It should be stated in passing that pure b-cell neogenesis is theoretically possible, but for various reasons, appears unlikely and not as desirable as neogenesis of fully functioning islets. Neogenesis used in the context of diabetes is therefore generally understood to refer to islets and not just insulinsecreting b cells.
Islet neogenesis can be achieved by at least two kinds of intervention. Gene therapy involves altering genomic DNA so that the development of islets is turned on in some way. This approach has the inherent limitations of any gene therapy targeted at somatic cells-the proportion of genetically altered cells will steadily decline as the progeny of non-altered cells overwhelm the latter. This therapy therefore would generally require repetitive administration. Gene therapy can target transcription factors involved in the earliest stages of islet developmental control, or gene therapy may function as a delivery approach for a trophic hormone that triggers islet formation at a downstream locus.
The more practical approach for inducing neogenesis is to expose embryonic or adult stem cells/progenitor cells to conditions that will cause these cells to differentiate into islets. This could involve removing tissue, such as bone marrow 31 or spleen, 32 treating it in some manner, and reinjecting the activated stem cells contained therein either locally or systemically. More plausibly, trophic agents would be administered to activate stem cells that are further committed toward islet differentiation and are located within pancreatic tissue.
Embryogenesis and Development of Islets
Stem cells have the ability to divide in a way that leads to both differentiation of its progeny and maintenance of the stem cell population. It appears that truly undifferentiated or totipotent stem cells appear at the blastocyst stage of embryogenesis. During development, these early stem cells lose their totipotency to varying degrees. It is now well established that stem cells must exist in some form in every tissue that depends on cellular division to maintain its integrity. 33 In this context, the modifiers, stem and progenitor, have similar meanings but somewhat different connotations. A "progenitor cell" means a cell that is relatively more immediately proximate to the fully differentiated cell than the "stem cell" of the same tissue.
The embryonic development of the pancreas in mice illustrates the general concept of functional tissue developing from stem cells as well as the very relevant biology. The expression of various transcription factors is tied to the progressive differentiation of cells during development. These markers have allowed the delineation of progenitor cells into mature pancreatic cells. [34] [35] During fetal pancreatic organogenesis, the proliferation of endocrine cells ensues from progenitor cells and not by the division of fully differentiated endocrine cells 36 (Figure 2 ). There is some debate about the nature and role of progenitor cells in the adult pancreas. Some evidence supports that b-cell replication is the predominate means of maintaining adult b-cell mass. [37] [38] In addition to insulin-secreting b cells, islets contain a cells, which produce glucagon; g cells, which secrete pancreatic polypeptide; and d cells, which secrete somatostatin. [39] [40] 
Islet Progenitor Cells
Despite continuing debate about the role of b-cell replication, abundant evidence supports the existence of islet progenitor cells in adult animals. Neogenesis has been observed in reaction to various stresses, including induced hyperglycemia, 41 partial pancreatectomy, 42 and partial obstruction of the pancreas by cellophane wrapping, which led to the discovery of INGAP. 43 The neogenesis observed under these and other conditions appears to originate from the pancreatic ducts, which serve the exocrine function of this organ. 40
Induction of Differentiation to Islets
As evidence for the persistence of islet progenitor cells in the mature pancreas mounts, the search has continued for agents that could induce these progenitor cells to develop into islets. Indeed, evidence of neogenesis activity has been reported for a number of hormones in animal models, including insulin-like growth factor-1 (IGF-1), 44, 45 prolactin, 46 gastrin, [47] [48] [49] transforming growth factor-a, [50] [51] [52] [53] epidermal growth factor, 45, 47, 54 glucagon-like peptide-1 (GLP-1), [55] [56] [57] exendin-4, [58] [59] [60] [61] [62] and INGAP peptide. 26, 63, 64 It is important to note that some of these agents, such as GLP-1 and related agonists, directly influence metabolism. Their metabolic effect-lowering high levels of blood glucose-is mainly due to its stimulatory effect on insulin synthesis and release. They may thereby indirectly improve b-cell function through these metabolic effects in addition to direct trophic effects on the b cell. Demonstration of neogenesis in animal models does not necessarily mean that an agent is neogenic in humans. [65] [66] [67] 
Islet Neogenesis Associated Protein

History
Islet neogenesis associated protein is the first therapeutic candidate to be identified as the result of a purposeful search for an endogenous molecule with islet neogenic activity. 68 It was found that partial obstruction of the pancreatic duct of hamsters during surgery induced islet neogenesis. A parabiotic study, in which cross-circulation was surgically established between two animals-one with partial obstruction of the pancreatic duct-suggested that induction of cellular proliferation and differentiation involved paracrine signaling. 69 A neogenesis-promoting activity was identified under the condition of incomplete obstruction and partially purified from a soluble tissue fraction. The activity was termed ilotropin. 70 Using an mRNA differential display, a novel gene was identified, sequenced, and cloned. 71 The 168-kDa protein product of this gene was found to be a major constituent of the ilotropin extract and to be responsible for the neogenesis activity. 66 This molecule was then named islet neogenesis associated protein. 66, 72, 73 An active core sequence of 15 residues within INGAP was identified; antibodies raised against this peptide abolished the neogenesis activity in the ilotropin extract. Subsequent animal and human studies have been performed with this 15 amino acid peptide termed INGAP peptide. 66
INGAP-A Reg Protein
In parallel with INGAP research, investigations in different areas of interest converged with the discovery of the kinship of various regulatory proteins within and across species. A consequence of this interdisciplinary effort is that different names evolved for the same protein. Investigation of regeneration in the endocrine pancreas originated the Reg terminology. 74 A focus on exocrine proteins overexpressed during pancreatitis and other clinical conditions led to the names pancreatitis-associated proteins, 75 pancreatic thread protein, 76 pancreatic stone protein, 77 lithostathine, 75 and hepatocarcinoma-intestine-pancreas protein. [78] [79] The exocrine focus led to the observation that the production of certain nonenzymatic proteins in the acinar tissue rises during chronic or acute pancreatitis. 73, 80 A number of activities have been ascribed to these proteins. 73, [81] [82] [83] [84] [85] Increased circulating Reg levels have been associated with pancreatitis and cystic fibrosis, 78 but no correlation has been found between serum levels of Reg and clinical markers of pancreatitis such as trypsin and lipase. 86 Reg proteins fall into three families, each named for the patriarchal protein, Reg I, Reg II, Reg III, and Reg IV 87 (see Figure 3 ). INGAP from hamster and a similar protein in mice, INGAP-related protein, 88 89 Finally, all Reg proteins possess a C-type lectin moiety. 90 INGAP is closely related to Reg III proteins and is almost certainly a member of that family. 91 Reg III family members share a common five amino acid segment. Significantly, INGAP peptide shares this segment at the center of its 15 amino acid sequence. 66 Based on structural models, this segment would likely be found on an outside turn in the three-dimensional structure of the protein. 92 It has been suggested that the presence of this segment might substantially affect ligand binding by altering the distribution of these proteins. 90 A given species may have two or more Reg proteins in the same Reg family. For example, mice have two Reg I members (Reg I and Reg II) and four Reg III members (Reg3a, Reg3b, Reg3d, and Reg3g). In humans, Reg1a and Reg 1b are Reg I members, and Reg3a and Reg3g are Reg III members. Reg proteins are widely distributed throughout the body, although expression patterns differ for individual family members. 89 In addition to the observed trophic effects of the pancreas, Regs have been implicated as neurotrophic agents. [93] [94] [95] This activity is conceivably linked to observations suggesting that pancreatic sensory nerves have a fundamental etiologic role in islet autoimmunity. [96] [97] 
Reg Proteins and Islet Biology
Growing evidence links INGAP and other Reg proteins to the developmental control of both exocrine and endocrine tissue of the pancreas. Reg proteins are mitogenic in both islet and ductal cell lines, as well as in isolated islets and primary duct cultures. 66, 98, 99 These proteins also have anti-apoptotic properties, specifically against oxidative stress. 82, 100 Most relevant is the association of Reg proteins with regeneration of pancreatic tissue. Reg I was first identified with screening of a rat islet cDNA library under conditions of islet regeneration. 74 Some Reg protein expression has been found in regenerating islets, 101 but most expression occurs in acinar tissue. 102 Reg I treatment improved glycemia in a surgically induced model of diabetes 103 and reduced the progression to diabetes in the nonobese diabetic (NOD) mouse model. 104 Increased endogenous Reg expression correlated with a delayed onset or prevention of overt diabetes in NOD mice. [105] [106] [107] Reg genes are upregulated under multiple conditions of bcell mass expansion and regeneration, including pancreasspecific IGF-1 knockout mice, 108 exendin-4 administration, and partial pancreatectomy. 109 It is interesting that a Reg I knockout mouse appeared to be normal except for a reduction in the proliferative index of isolated islets. The response to stimuli of islet proliferation was also reduced in these animals. 110 However, islet proliferation was noted in transgenic mice expressing Reg I behind the insulin promoter. This Reg I transgenic mouse was crossed with NOD mice to produce NOD mice carrying the Ins-Reg transgene. It was found that development of diabetes was significantly retarded and b-cell mass increased in the resulting Ins-Reg transgenic progeny. 64 In yet another transgenic construct, INGAP was placed behind
INGAP Experimental Data
The identification of INGAP as an important element in the developmental biology of islets has led to three major lines of investigation: (1) 
Studies of Endogenous INGAP
Hamster INGAP immunoactivity has been noted in the pancreatic tissue of normal hamsters. Most of this activity is seen in acinar tissue while some activity is located within the exocrine ducts and on the periphery of islets, but not within them. Some INGAP expression was found within islet cells but coexpression of islet hormones within these cells was not seen. 113 In hamsters, sucrose added to the drinking water causes increased insulin secretion and b-cell mass while normoglycemic blood levels are maintained. The presence of cytokeratin-positive (CK+) cells within the islets and other evidence suggest that islet neogenesis contributes to the increased b-cell mass. During the conditions of this model, INGAP expression increased in the three pancreas subsectors, namely acinar, ductal, and islet cells. INGAP expression was also associated with glucagon-positive cells in the periphery of islets, with cells of the acinar compartment, and frequently with CK+ cells. 114 Sucrose administration to pregnant hamsters led to postnatal hyperinsulemia and lower serum glucose levels (but not hypoglycemia) in their pups from the increased b-cell mass that was induced by the in utero sucrose exposure. b-cell proliferation and islet neogenesis increased significantly in these animals. 115 These hamster pups also showed a striking increase in the frequency of pancreatic and duodenal cells positive for homeobox gene-1 (PDX1). Within the pancreas, this marker of islet progenitor cells was observed in both ductal and extra-insular cells. A subset of these PDX1+ cells was also positive for INGAP expression. These PDX1+/INGAP+ cells were found to be negative for all islets hormones and have a very high replication rate, thus suggesting that they probably were early precursor cells. This phenotype accounted for most of the increase in duct-and acinarassociated PDX1+ cells. This cellular phenotype provides evidence for a subpopulation of islet progenitors that express INGAP. 111
Relevant Data from Other Rodents
Lipsett and Finegood have developed a model of bcell neogenesis in a rat model based on chronic glucose infusion. 116 Immunohistology of tissue from their original study using a polyclonal anti-Reg3a antibody revealed staining localized in the ducts, but also in acini. Peak activity occurred about 48 hours prior to the observed increase in b-cell mass. 6 Wang and colleagues suggested the BioBreeding (BBdp) rat as another neogenesis model. They noted an increased abundance of tubular complexes in these animals during the progression of metabolic disease. 117 These tubular complexes are postulated to be the result of acinar-to-duct dedifferentiation. [118] [119] [120] [121] [122] After observing both amylase+/CK+ and CK+/insulin+ cells and increased expression of both stem and endocrine progenitor cell markers, the authors concluded that the tubular complexes reflected regeneration via islet neogenesis. Subsequent immunohistochemistry of tissues from these pups revealed Reg3a staining of ducts and acinar tissue. Staining within tubular complexes was particularly prominent. 123 These results from two different rat models support the role of a Reg protein closely related to INGAP in islet neogenesis. The temporal sequence of Reg3 expression and neogenesis is consistent with an inductive role of Reg proteins in the neogenesis process.
INGAP Peptide Treatment in Rodents
Daily intraperitoneal injection of normoglycemic hamsters with INGAP peptide was associated with evidence of islet neogenesis within 10 days after start of treatment. 64 Evidence of neogenesis included increases in islet frequency, total b-cell mass, and both duct-and acinar-associated bcell mass. This expansion of b-cell mass continued for at least 30 days and then appeared to reach a plateau.
As a requirement for performing clinical trials, acute and subchronic toxicology studies were performed in mice, dogs, and monkeys. These studies provided the opportunity to evaluate INGAP activity in healthy animals. Examination of evidence for islet neogenesis included quantification of b-cell mass and tissue insulin content. In the 90-day study conducted in healthy mice, a dose-related increase in both duct-and acinar-associated single or small b-cell clusters was observed. A similar pattern was seen for focal areas of neogenesis (FANs), a term originally described in diabetic animals by Lipsett and Finegood. 116 Dose-related increases in FANs were associated with both ducts and acinar tissue. The peak effect was generally reached in the 100-mg/kg treated animals with no further increase in the 200-mg/kg animals. 124 These structures are thought to reflect neogenic activity. 42, 125 Peak effects were generally reached in animals dosed at 100 mg/kg daily, with no further increase noted in the 200-mg/kg group. Additional results are included later under the discussion of the monkey results.
INGAP peptide was tested in hyperglycemic mice rendered diabetic by streptozotocin. Hyperglycemia was reversed by 6 weeks in all four animals receiving INGAP peptide treatment. Significant increases were observed in ductaland acinar-associated neogenesis and b-cell mass. 116 Nonobese diabetic mice were treated with INGAP peptide to evaluate activity in an established model of T1DM. Because these animals have an intense islet autoimmunity as the cause of diabetes, it was questioned whether INGAP peptide treatment alone could induce a neogenic response. The animals therefore received INGAP peptide (500 mg every day intraperitoneally) alone or with immunosuppression (0.1 mg/kg tacrolimus + 0.1 mg/kg sirolimus every day by gavage). In contrast to the acutely diabetic NOD mice used in most immune intervention studies, 126 the animals in this study were chronically diabetic with blood glucose levels >28 mM for 6 weeks before treatment was begun. The animals used in the study therefore approximated chronic diabetes, which presumably would be more resistant to therapy than new-onset diabetes. INGAP peptide alone was found to improve glycemia and there was some additional effect shown with INGAP peptide in combination with immunosuppression as compared to immunosuppression alone. Moreover, compared to immunosuppression only, treatment with INGAP peptide prolonged survival of these animals. 123
INGAP Peptide in Healthy Dogs
In addition to the 90-day toxicology study in mice mentioned earlier, a 34-day toxicology study of INGAP peptide was conducted in healthy dogs (but unlike in mice and monkeys, no 90-day dog study was conducted). In this shorter dog study and consistent with the findings in mice, FANs were observed at the top 10-mg/kg dose group. A dose-ranging study of INGAP peptide was performed in 40 dogs (20 males, 20 females). They were randomized to four daily injected treatment groups (vehicle alone, 0.5, 1.5, or 10 mg/kg INGAP peptide). After 30 days of treatment, pancreatic tissues were analyzed with immunohistochemistry for insulin content, PDX-1 (the essential islet transdifferentiation transcription factor) and PGP9.5 (a pan-neuroendocrine marker).
In animals treated with INGAP peptide, the percentage of insulin positive cells increased significantly. The 1.5-mg/kg dose produced the highest response-more than doubling the frequency of the controls (p < 0.05). Females were also found to be significantly (p < 0.01) more responsive than males to the peptide. PGP9.5 staining was increased in large ducts of treated animals, suggesting development of neuroendocrine cells from ductal elements in response to INGAP peptide. PDX-1 was found in isolated cells in ducts and was increased in treated pancreas as well. The increased concurrent expression of PDX-1 in duct cells suggests a role for INGAP at an early stage in islet development.
INGAP Peptide in Healthy Monkeys
As mentioned earlier, a 90-day toxicology study was conducted in healthy cynomolgus monkeys. As in the mouse and dog toxicology studies, pancreatic tissue was examined for evidence of islet neogenesis and included quantification of b-cell mass and tissue insulin content. As was the case in mice and dogs, no difference in total b-cell mass or tissue insulin content was seen in the monkey toxicology study. The presence of FANS in monkeys was more sporadic in dogs, but even more significant in its therapeutic implications for humans. An area of neogenesis, as characterized by a large region of tubular complex formation, was observed in 4 out of 10 monkeys administered the high dose of INGAP peptide (400 mg/kg body weight per day). This area appeared to involve a full pancreatic lobule and the majority of this area was positive for insulin.
Although the study populations are small, these data taken together suggest that INGAP peptide has neogenesis activity in normal animals, which could be expected to be more resistant to induced neogenesis activity than diabetic animals. Similar to other tissues, b-cell mass in the absence of disease appears to be maintained at relatively constant levels but changes in response to physiologic or environmental conditions as needed. [127] [128] [129] This is likely achieved in normal animals by multiple levels of control applied to islet neogenesis and b-cell growth, atrophy, mitosis, and apoptosis. 130 The lack of observed net increases in b-cell mass in the face of induced neogenesis in these animals could plausibly be explained by the homeostatic control of these processes. 127, 131, 132 Perhaps more important to supporting the potential value of INGAP peptide as a therapy for people with diabetes is the direct observation of neogenesis attributable to this peptide in another primate. Comparison of responses to INGAP peptide in monkey and mouse suggests some difference in neogenesis potency.
Effects of INGAP in Human Tissue Culture
Evidence for the neogenic potential of INGAP peptide in humans comes from observations made using cultured human tissue. After isolation of adult human islets, specific culture conditions are used to induce a phenotypic change to highly proliferative duct-like structures (DLS), characterized by the loss of expression of islet-specific hormones and transcription factors, as well as appearance of markers of both duct epithelial and progenitor cells. Based on electron microscopy and immunofluorescent staining, it would appear that transdifferentiating a and d cells and, to a lesser degree, pancreatic polypeptide cells give rise to the cells of the DLS. Short-term treatment of undifferentiated DLS with INGAP peptide induces their redifferentiation back to islet-like structures (ILS). These ILS resemble freshly isolated human islets with respect to morphology, islet gene expression, hormone production, insulin content, and glucose-stimulated insulin secretion. 26, 133 This approach extends a fascinating line of investigation, which has broad significance to developmental biology in general and for practical therapeutic applications, which are discussed later. This work and others establish the plasticity of the developmental system that generates and maintains the endocrine and exocrine tissues of the pancreas. [134] [135] [136] [137] [138] Presumably the demonstration that INGAP peptide can induce human-derived tissue to differentiate into functionally normal islets predicts that humans have the signaling elements necessary for responsiveness to the neogenic effects of INGAP. These data also indirectly support that adults continue to have potentially responsive progenitor cells within the pancreas (Figure 4) .
This human-derived tissue also provides a basis for an in vitro assay for neogenesis activity. Use of this assay has produced some intriguing if not surprising results: while a synthetic peptide derived from a hamster protein, INGAP peptide, is sufficient to induce neogenesis, the corresponding peptide sequences from the human homologues, Reg3a and Reg3g, do not exhibit this activity. Moreover, islet regeneration in this model is unresponsive to GLP-1, but does respond to both gastrin and hepatocyte growth factor. 139 Preliminary data also show that Reg3a does not have activity in this assay. 123 Some recent clinical observations are relevant. Reg III protein has been implicated in the case report of hyperinsulinemia following pancreatic transplant. Florid nesidioblastosis, a rare condition of islet hyperplasia almost always confined to very young children, was found in this patient's pancreas. Neogenic tissue demonstrated heavy staining with a Reg III antibody raised against INGAP 140 but this likely reflects the presence of a closely related Reg III protein. Among the reports of gastric bypass-associated nesidioblastosis cited earlier, these tissues also stained very heavily with this same antibody.
Figure 4:
A speculative model for progenitor cell development similar to Figure 1 but with apparent sites indicated for induction by trophic agents. Evidence for these sites and relationships comes primarily from rodent studies. The existence of a pluripotent neuroendocrine cell is suggested by some data but has not been established. Available evidence suggests that humans differ in responsiveness to trophic agents. INGAP appears to work relatively early in this cascade. Used with permission from Gary Pittenger.
Other Effects of INGAP
Before discussing clinical data from INGAP peptide, it is noteworthy that INGAP peptide may have direct effects on b-cell function. It has been reported that INGAP peptide increases both basal and stimulated insulin secretion from isolated rat islets. 141 These effects were observed in islets from both neonatal and adult rats after as little as a 90minute incubation period. The maximum effect was reached over 4 days of incubation at concentrations in the mid to high nanomolar range. In contrast to GLP-1 agonists, these secretagogue effects were not associated with any effect on cell survival, although administration of INGAP peptide did induce hypertrophy but not hyperplasia of both b and non-b cells within the islet.
INGAP in Human Clinical Trials
Islet neogenesis associated protein peptide was first tested in a rising single-dose safety study. Thirty patients with T1DM or T2DM received single subcutaneous injections; dose levels were 0, 7.5, 15, 30, 60, and 120 mg. A second study administered 34 daily doses to 33 patients randomized to placebo, 7.5, 30, or 120 mg. These doses were well tolerated by all subjects. The half-life of INGAP peptide was determined to be about 90 minutes. There was no clear effect on basal or stimulated C-peptide levels at these phase 1 dose levels.
Two phase 2 trials, one in patients with T1DM and one in T2DM, were then conducted to evaluate the efficacy and safety of INGAP. These trials have been reported in abstracts and full publication is planned by the investigators. In both trials, subjects were randomized to injections of 300 or 600 mg of INGAP peptide versus placebo, and all received single subcutaneous injections for 90 days. The T1DM study enrolled 63 patients, and the T2DM study enrolled 126 patients. The primary efficacy end point was the treatment effect on endogenous insulin secretion as measured by arginine-stimulated C-peptide at baseline and day 120, which was 30 days after end of treatment. HbA1c (measured at day 90 and day 120) and the average daily insulin dose were secondary end points.
In T1DM patients receiving 600 mg daily, there was an increase in stimulated arginine C-peptide response by day 56. The mean change from baseline approached statistical significance (p = 0.07) and the pair-wise comparison difference versus placebo was highly significant (p = 0.0058). For T2DM patients, there was no statistically significant difference in comparison to placebo for stimulated arginine C-peptide response, and essentially no changes were noted from baseline for the active treatments groups. By day 120, however, the placebo group declined significantly from baseline, resulting in a trend toward a significant difference in the pair-wise comparison of the 600-mg and placebo groups.
In the T1DM trial, overall glycemic control as measured by HbA1c decreased by 0.5 units from baseline to day 90 in the 600-mg treatment group (p < 0.01). HbA1c decreased slightly in the placebo and 300-mg groups. By day 120 (30 days after the end of therapy) about half of each of these treatment effects was lost. Average daily glucose levels, as determined by a self-monitored blood glucose meter, fell by 2.15% from baseline in the 600-mg group and rose 0.103% in the placebo at day 90. However, these changes did not reach statistical significance. In the T2DM trial, the effect on HbA1c of the 600-mg treatment group showed a pattern similar to that seen in the T1DM trial, but the effect was greater in magnitude (change from baseline = 0.91 HbA1c units) and greater in statistical significance (p < 0.01).
Although the placebo group also improved, the pair-wise comparison was still statistically significant (p = 0.04) and the difference (treatment effect) was 0.55 HbA1c units (0.8 HbA1c units for the difference between 300-and 600-mg groups). In support of this finding, the 600-mg group mean daily glucose levels as determined by a self-monitored blood glucose meter fell by 9.8% from baseline and 12.6% from placebo at day 90 (p < 0.01).
In both trials, no consistent treatment effects on fasting glucose, insulin, and C-peptide were seen. In the T1DM trial, the total insulin dose did appear to fall in a dosedependent manner from baseline to day 90 with changes of +0.10, -0.28, and -2.15% for the placebo, 300-mg, and 600-mg groups, respectively. The treatment effect for the 600-mg group was about 1.0 unit. However, none of these baseline or pair-wise comparisons was statistically significant.
No effect on insulin dose was observed in the T2DM trial.
Anti-GAD antibody titers were monitored in both trials to assure that islet cell destruction was not being stimulated.
In the T1DM trial, five, seven, and four patients in each treatment group had positive tests at baseline. Two patients in the 300-mg dose group showed an increase in titer by the end of the study, and one patient in the 600-mg group who had a negative result at baseline converted to seropositive.
Injection site reactions were common and contributed to a significant drop-out rate. T2DM patients had less injection site reactions than T1DM patients. Except for these injection site reactions, the treatment was well tolerated and no evidence of systemic toxicity was observed.
The patterns of response for the two major measures of efficacy-stimulated C-peptide and HbA1c-were similar across both trials, but differed in levels of statistical significance. The latter can be explained by differences between the trials in statistical power for these outcomes. The low variability of the baseline C-peptide levels in the T1DM trial resulted in greater statistical power for this outcome than for the T2DM trial, in which variability was very high. Variability of HbA1c was similar across both studies, but the T2DM trial had twice the number of randomized subjects and fewer drop outs than the T1DM trial. It is therefore possible that the underlying biologic effects of treatment were similar in both studies. The best evidence for islet neogenesis per se comes from the highly statistically significant treatment effect on stimulated C-peptide secretion and the trend toward a reduction in insulin dose seen in the T1DM study. The absolute effect on this measure of endogenous insulin secretion was small but approaches clinical meaningfulness as discussed by Palmer et al. 142 Given the once-daily injection used in this trial and the relatively short half-life of the peptide, it is likely that better results and/or improved bioefficacy could be achieved with multiple daily injections, constant infusion, or a depot formulation.
Unanswered Questions and Looking Forward
Much progress has been made in understanding the mysteries of islet biology among vertebrates. Within the context of human health and disease, however, unanswered questions surrounding the birth, development, and death of islets abound. The encouraging conclusion is that humans incontrovertibly have, under some circumstances, the capacity for islet neogenesis. Neogenesis therapy is therefore not a matter of "if" but of "when" and "how." Short of a safe, fully effective, and practical prevention of T1DM, islet neogenesis or a related form of stem cell therapy is a necessary, although probably not entirely sufficient, means of curing T1DM. Therapeutic control or reversal of islet autoimmunity will likely be an important adjunct to any neogenesis treatment of established T1DM. For people with incipient or established T1DM, immunomodulatory therapy can only preserve what secretory function remains, which is typically very little in most T1DM and many T2DM patients today. Many people with insulin-dependent T2DM also have minimal remaining b-cell function. Functioning islet tissue can be surgically returned in the form of either human or encapsulated animal islets, but these have significant limitations and technical challenges. Autologous ex vivo regeneration and transplantation of islets is a hybrid and intermediate approach that also requires a means of inducing neogenesis.
While the need of a neogenesis therapy for people with T2DM is not as pressing as for those with T1DM, it is still important and is anticipated to become increasingly important for younger patients with T2DM. Although therapies are now available that slow the progressive loss of b-cell function, preliminary evidence suggests that these therapies will not restore lost function. To the extent that b-cell function continues to decline, despite the use of these therapies, a safe and effective neogenesis therapy will be important in restoring health in people with T2DM.
Is INGAP peptide a practical therapeutic approach? The available evidence is encouraging. Optimization of the therapy and more evidence are needed. An associated puzzle persists, and it goes to the heart of understanding why humans lose the capacity to regenerate lost islets. Although abundant evidence in other animals suggests the importance of Reg proteins to normal islet development, the endogenous expression of human Reg proteins, at least during islet autoimmunity, does not lead to clinically meaningful islet regeneration. Furthermore, some preliminary evidence indicates that the homologue of INGAP, Reg3a, and its corresponding sequence to INGAP peptide have no neogenesis activity in a human islet-derived in vitro assay. However, a closely related but nonendogenous protein, INGAP, and its core pentapeptide do show evidence of neogenesis activity in several species, including humans. Resolving this apparent paradox with dissection of structure/function relationships among the cross-species signaling pathways could lead to more effective and convenient therapeutic approaches. The urgent needs are to optimize therapy of a molecule in hand that has shown evidence of safety and efficacy and, if safety and effectiveness are confirmed, to deliver this new therapy to people who need it. Optimized INGAP peptide therapy is unlikely to be the ultimate neogenesis agent, but it may well lead to it. The quest for a fundamental restorative approach to lost insulin secretion is an achievable goal, but one that will be reached by taking steps, not leaps.
